… widely, which is generic products and biosimilars, when they are appropriate to be released because patents have expired, should allow a competition, not a crony capitalism to run the market. The current system has slowed the ability of insurgents to enter the market. And that stops today under the leadership of Dr. Makary. Now CMS job is to pay the bills. We focused on improving reimbursement models. (20:17–20:22)
CLAIM
Asserts that the current system hinders new competitors from entering the pharmaceutical market.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
